Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study

As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgent need for new and effective therapeutic alternatives for selected cases with severe disease. Bortezomib (BTZ) is a specific, reversible, inhibitor of the 20S subunit of the proteasome. Herein, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Walhelm, Tomas, Gunnarsson, Iva, Heijke, Rebecca, Leonard, Dag, Trysberg, Estelle, Eriksson, Per, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517506/
https://www.ncbi.nlm.nih.gov/pubmed/34659263
http://dx.doi.org/10.3389/fimmu.2021.756941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517506/
https://www.ncbi.nlm.nih.gov/pubmed/34659263
http://dx.doi.org/10.3389/fimmu.2021.756941

Ejemplares similares